ArticleBlood2017
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
2 registry-linked trialsAbstract readClinical Trial, Phase ILetterMulticenter Study
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies
A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Trial
- New Means and Challenges in the Targeting of BTK.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Review
- B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.Frontiers in oncology · 2024Review
- A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications.Molecules (Basel, Switzerland) · 2023Review
- Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.International journal of hematology · 2023Article
- The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.Cancers · 2022Review
- Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.Targeted oncology · 2022Review
- Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.Drug design, development and therapy · 2022Review
- Review
- Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.Frontiers in cell and developmental biology · 2021Review
- Managing toxicities of Bruton tyrosine kinase inhibitors.Hematology. American Society of Hematology. Education Program · 2020Review
- Tirabrutinib: First Approval.Drugs · 2020Review
- Amelioration of age-related brain function decline by Bruton's tyrosine kinase inhibition.Aging cell · 2020Article
- Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?Blood advances · 2019Article
- Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.Cancer science · 2019Article
- From Biology to Therapy: The CLL Success Story.HemaSphere · 2019Review
- Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.Targeted oncology · 2019Review
- The Treatment of Chronic Lymphatic Leukemia.Deutsches Arzteblatt international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Harriet S WalterErnest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.ORCID 0000-0003-2618-711X
Sandrine JayneErnest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.ORCID 0000-0003-1870-9782
Simon A RuleDepartment of Clinical Haematology, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom.ORCID 0000-0001-8937-6351
Guillaume CartronDepartment of Clinical Hematology and Unité Mixte de Recherche-Centre National de la Recherche Scientifique 5235, Centre Hospitalier Régional Universitaire, Montpellier, France.
Franck MorschhauserEA 7365 Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University of Lille, Lille, France.ORCID 0000-0002-3714-9824
Salvador MacipErnest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.ORCID 0000-0003-1963-8840
Lionel KarlinHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre-Bénite, Université Claude Bernard Lyon 1, Lyon, France.
Ceri JonesCardiff Chronic Lymphocytic Leukemia Research Group, School of Medicine, Cardiff University, Cardiff, United Kingdom; and.
Charles HerbauxEA 7365 Groupe de Recherche sur les Formes Injectables et les Technologies Associées, University of Lille, Lille, France.
Philippe QuittetDepartment of Clinical Hematology and Unité Mixte de Recherche-Centre National de la Recherche Scientifique 5235, Centre Hospitalier Régional Universitaire, Montpellier, France.
Nimish ShahDepartment of Clinical Haematology, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom.
Claire V HutchinsonErnest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.
Christopher FeganCardiff Chronic Lymphocytic Leukemia Research Group, School of Medicine, Cardiff University, Cardiff, United Kingdom; and.ORCID 0000-0001-9685-0621
Yingsi YangGilead Sciences, Inc, Foster City, CA.
Siddhartha MitraGilead Sciences, Inc, Foster City, CA.
Gilles SallesHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre-Bénite, Université Claude Bernard Lyon 1, Lyon, France.ORCID 0000-0002-9541-8666
Martin J S DyerErnest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.ORCID 0000-0002-5033-2236
Funding
Cancer Research UKMedical Research Council MC_U132670597
Abstract
PubMed holds no abstract for this paper.
Indexed as
Agammaglobulinaemia Tyrosine KinaseDisease-Free SurvivalFemaleFollow-Up StudiesHumansImidazolesLeukemia, Lymphocytic, Chronic, B-CellMaleProtein-Tyrosine KinasesPyrimidinesSurvival RateAgammaglobulinaemia Tyrosine KinaseImidazolesProtein-Tyrosine KinasesPyrimidinestirabrutinib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02457559ClinicalTrials.gov
NCT02457598ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.